Merck has demonstrated notable performance over the long term, prompting questions from investors regarding whether its current market valuation properly aligns with anticipated earnings and cash returns. Over a five-year period, the stock recorded a total return of 104.3%. Recent developments, including favorable clinical data for oncological therapies such as KEYTRUDA and sacituzumab tirumotecan—which secured FDA priority review during the year—as well as corporate portfolio shifts like a planned contract development and manufacturing organization (CDMO) divestment, help shape expectations for durable and diversified future cash generation. Meanwhile, the company's price-to-earnings ratio stands at 147.5x.
To evaluate whether the market price is supported by intrinsic value, a Discounted Cash Flow (DCF) model can be utilized. The company's latest twelve-month free cash flow is approximately $14.8 billion. Projections within the model scale this figure upward to slightly over $24 billion in annual free cash flow by the year 2030, pointing toward a steady but measured growth profile for the major pharmaceutical enterprise. When discounted back, these projected cash flows place the estimated intrinsic value of Merck above its current share price of $146.73.
Differing perspectives exist regarding the future trajectory of the stock. Optimistic projections suggest the enterprise is undervalued, linking future performance to a pipeline expected to introduce more than 20 new growth drivers, with management highlighting over $70 billion in non-risk-adjusted mid-2030s revenue potential from this next-generation portfolio. Conversely, cautious perspectives argue the equity is overvalued, contending that current market pricing already accounts for a seamless transition past the loss of exclusivity for KEYTRUDA while depending heavily on upcoming product launches and label expansions.
